MedTrace Logo

Mechanism-based Choice of Therapy for Neuropathic Pain

NCT01359514 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-10-11

No results posted yet for this study

Summary

Mechanism-based choice of therapy for neuropathic pain:

Can treatments success in neuropathic post-operative pain be coupled to psychophysical pain modulation profile?

Conditions

Interventions

DRUG

Pregabalin

Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks

DRUG

Duloxetine

Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • David Yarnitsky, Professor · Rambam Health Care Campus

  • Michal Granot, PhD · Haifa University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01359514 on ClinicalTrials.gov